The signaling plasticity offered by these SRC-dependent mechanisms may usurp and/or reinforce cell-autonomous pathways that drive tumor survival while bypassing other dependencies, including under the influence of BRAF/MEK or EGFR targeted therapies. The gene discussed is EGFR; the disease is neoplasm.